comparemela.com

Latest Breaking News On - Structural heart disease - Page 1 : comparemela.com

Edwards Lifesciences Q1 Earnings: Mixed Results with Adjusted EPS Beating Estimates

Abbott Receives FDA Approval for TriClip™, First-of-its-Kind Device to Repair Leaky Tricuspid Heart Valve

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's first-of-its-kind TriClip™ transcatheter edge-to-edge repair (TEER) system that's specifically designed for the treatment of tricuspid regurgitation (TR), or a leaky tricuspid valve. This approval follows .

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.